Allergan eyelash drug promotion misleading; FDA says company downplayed safety risks
As reported by Reuters, an Allergan Inc website for a drug to lengthen eyelashes downplayed potential side effects such as redness and changes in eye color, U.S. health officials said in a letter released on September 16.
The website and other promotional material developed by Allergan “are misleading because they omit and minimize risks associated with Latisse,” the Food and Drug Administration said in a Sept. 10 letter to the company.
With reference to Allergan’s Latisse, a once-a-day prescription drug approved in December 2008 for lengthening and thickening eyelashes, the FDA indicated that certain pages on the Latisse website for consumers failed to mention risks such as a bacterial infection if the drug or applicators become contaminated. The web pages also minimized eye redness and itching because they suggested those conditions were not associated with allergic reactions related to the treatment, the FDA said.
The FDA asked Allergan to immediately stop using the materials.
Related posts:
